Hyperphosphataemia in patients with chronic renal
failure on haemodialysis or continuous ambulatory
peritoneal dialysis (CAPD) | Hyperphosphataemia in
patients with chronic kidney disease not on dialysis who
have a serum-phosphate concentration of
1.78 mmol/litre or more that cannot be controlled by a
low-phosphate diet
▶BY MOUTH
▶Adult: 1.5–3 g daily in divided doses, dose to be
adjusted according to serum-phosphate concentration
every 2–3 weeks, to be taken with or immediately after
meals
PDF page 1137
Scottish Medicines Consortium (SMC) decisions
SMC No. 286/06
The Scottish Medicines Consortium has advised (May 2007)
that lanthanum chewable tablets (Fosrenol ®) are accepted
for restricted use within NHS Scotland for the control of
hyperphosphataemia in patients with chronic renal failure
on haemodialysis or continuous ambulatory peritoneal
dialysis, as a second-line agent, where a non-aluminium,
non-calcium phosphate binder is required.
SMC No. 640/10
The Scottish Medicines Consortium has advised (October
2010) that lanthanum (Fosrenol ®) is not recommended for
use within NHS Scotland for the control of
hyperphosphataemia in patients with chronic kidney
disease not on dialysis with serum phosphate levels
1.78mmol/L in whom a low phosphate diet alone is
insufficient to control serum phosphate levels, as the
clinical and economic analysis presented was not
demonstrated.
SMC No. 821/12
The Scottish Medicines Consortium has advised
(December 2012) that lanthanum oral powder (Fosrenol ®)
is accepted for restricted use within NHS Scotland as a
second-line agent in the control of hyperphosphataemia in
chronic renal failure patients on haemodialysis or CAPD
where a non-aluminium, non-calcium phosphate binder is
required.
PDF page 1137
